"Das Epilepsie-Zentrum im Krankenhaus Mara kooperiert mit allen Kliniken, Instituten und interdisziplinären Zentren des Evangelischen Klinikums Bethel (EvKB), um Patienten die beste medizinische Versorgung bieten zu können. Im Epilepsie-Zentrum erhalten Betroffene alle Diagnose- und Behandlungsmöglichkeiten auf dem neuesten medizinischen Stand."

During the past decade, Krankenhaus Mara gGmbH - Epilepsiezentrum Bethel conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 5 clinical trials were completed, i.e. on average, 71.4% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 3 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Krankenhaus Mara gGmbH - Epilepsiezentrum Bethel" #1 sponsor was "Takeda" with 3 trials, followed by "Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc." with 3 trials sponsored, "SK Life Science, Inc." with 2 trials sponsored, "Cyberonics, Inc." with 1 trials sponsored and "Pfizer's Upjohn has merged with Mylan to form Viatris Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Krankenhaus Mara gGmbH - Epilepsiezentrum Bethel" #1 collaborator was "PRA Health Sciences" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Krankenhaus Mara gGmbH - Epilepsiezentrum Bethel" are "Dravet Syndrome" (3 trials), "Dravet Syndrome (DS)" (2 trials), "Lennox Gastaut Syndrome (LGS)" (2 trials), "Partial Epilepsy" (2 trials) and "Epilepsies, Partial" (1 trials). Many other conditions were trialed in "Krankenhaus Mara gGmbH - Epilepsiezentrum Bethel" in a lesser frequency.

Most popular intervention types in "Krankenhaus Mara gGmbH - Epilepsiezentrum Bethel" are "Drug" (9 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Soticlestat" (3 trials), "ZX008 (Fenfluramine Hydrochloride)" (3 trials), "Matching Placebo" (2 trials) and "YKP3089" (2 trials). Other intervention names were less common.

The vast majority of trials in "Krankenhaus Mara gGmbH - Epilepsiezentrum Bethel" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Krankenhaus Mara gGmbH - Epilepsiezentrum Bethel". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Krankenhaus Mara gGmbH - Epilepsiezentrum Bethel, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Krankenhaus Mara gGmbH - Epilepsiezentrum Bethel, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".